Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Common Equity (2018 - 2025)

Historic Common Equity for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $618.5 million.

  • Bicycle Therapeutics' Common Equity fell 2557.7% to $618.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.5 million, marking a year-over-year decrease of 2557.7%. This contributed to the annual value of $793.1 million for FY2024, which is 11380.2% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Common Equity of $618.5 million as of Q3 2025, which was down 2557.7% from $668.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Common Equity ranged from a high of $873.8 million in Q2 2024 and a low of $142.0 million during Q2 2021
  • Moreover, its 5-year median value for Common Equity was $346.3 million (2021), whereas its average is $428.2 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 2931.84% in 2023, then soared by 29701.27% in 2024.
  • Over the past 5 years, Bicycle Therapeutics' Common Equity (Quarter) stood at $346.3 million in 2021, then decreased by 21.8% to $270.8 million in 2022, then soared by 36.98% to $370.9 million in 2023, then surged by 113.8% to $793.1 million in 2024, then fell by 22.01% to $618.5 million in 2025.
  • Its last three reported values are $618.5 million in Q3 2025, $668.9 million for Q2 2025, and $740.3 million during Q1 2025.